Last reviewed · How we verify
NCT04599647
EAP for the Treatment of Glioblastoma With PVSRIPO
trial testing PVSRIPO in Glioblastoma. No longer available.
Quick facts
| Lead sponsor | Istari Oncology, Inc. |
|---|---|
| Status | NO LONGER AVAILABLE |
| Study type | EXPANDED_ACCESS |
| Sites | 1 location across United States |
Drugs / interventions tested
- PVSRIPO — full drug profile →
Conditions studied
- Glioblastoma — all drugs for Glioblastoma →
Sponsor
Istari Oncology, Inc. — full company profile →
Who can join
18 and older, any sex, with Glioblastoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an open-label, single-arm, non-randomized, intermediate-sized expanded access study evaluating the safety, efficacy, and tolerability of PVSRIPO delivered via intratumoral infusion, in subjects with glioblastoma (GBM) who are ineligible to participate in clinical study with PVSRIPO that is currently open to enrollment.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Current Status and Challenges of Oncolytic Virotherapy for the Treatment of Glioblastoma.
Webb MJ, Sener U, Vile RG. · · 2023 · cited 20× · PMID 37375742 · DOI 10.3390/ph16060793 -
Device-assisted strategies for drug delivery across the blood-brain barrier to treat glioblastoma.
Mokarram N, Case A, Hossainy NN, Lyon JG, et al · · 2025 · cited 17× · PMID 39790893 · DOI 10.1038/s43246-024-00721-y
Verify or expand the search:
- PubMed search for NCT04599647
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of PVSRIPO
Trials testing the same drug.
- NCT04125719 — PVSRIPO in Combination With Nivolumab in Melanoma · Phase 1 · withdrawn
- NCT03564782 — Examining Bioactivity of PVSRIPO in Invasive Breast Cancer · EARLY_PHASE1 · completed
- NCT03712358 — PVSRIPO for Patients With Unresectable Melanoma · Phase 1 · terminated
Other recruiting trials for Glioblastoma
Currently open trials in the same condition.
- NCT07284069 — Senicapoc and Perampanel for Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
- NCT05653635 — Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study · Phase 2 · recruiting
- NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
- NCT07448480 — Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas · active not recruiting
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
Other Istari Oncology, Inc. trials
Trials by the same sponsor.
- NCT04690699 — LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors · Phase 1, PHASE2 · terminated
- NCT04577807 — LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma · Phase 2 · completed
- NCT04479241 — LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma · Phase 2 · completed
- NCT03564782 — Examining Bioactivity of PVSRIPO in Invasive Breast Cancer · EARLY_PHASE1 · completed
- NCT03712358 — PVSRIPO for Patients With Unresectable Melanoma · Phase 1 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04599647 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Istari Oncology, Inc.
- Last refreshed: 29 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04599647.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing